Drucker D J, Lovshin J, Baggio L, Nian M, Adatia F, Boushey R P, Liu Y, Saleh J, Yusta B, Scrocchi L
Department of Medicine, Toronto General Hospital, Banting and Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada M5G2C4.
Ann N Y Acad Sci. 2000;921:226-32. doi: 10.1111/j.1749-6632.2000.tb06970.x.
Glucagon-like peptides 1 and 2 (GLP-1 and GLP-2) are coencoded within a single mammalian proglucagon precursor, and are liberated in the intestine and brain. GLP-1 exerts well known actions on islet hormone secretion, gastric emptying, and food intake. Recent studies suggest GLP-1 plays a central role in the development and organization of islet cells. GLP-1 receptor signaling appears essential for beta cell signal transduction as exemplified by studies of GLP-1R-/- mice. GLP-2 promotes energy assimilation via trophic effects on the intestinal mucosa of the small and large bowel epithelium via a recently cloned GLP-2 receptor. The actions of GLP-2 are preserved in the setting of small and large bowel injury and inflammation. The biological actions of the glucagon-like peptides suggest they may have therapeutic efficacy in diabetes (GLP-1) or intestinal disorders (GLP-2).
胰高血糖素样肽1和2(GLP-1和GLP-2)在单一哺乳动物胰高血糖素原前体中共编码,并在肠道和大脑中释放。GLP-1对胰岛激素分泌、胃排空和食物摄入具有众所周知的作用。最近的研究表明,GLP-1在胰岛细胞的发育和组织中起核心作用。如对GLP-1R-/-小鼠的研究所表明的,GLP-1受体信号传导似乎对β细胞信号转导至关重要。GLP-2通过最近克隆的GLP-2受体对小肠和大肠上皮的肠粘膜产生营养作用,从而促进能量同化。在小肠和大肠损伤及炎症情况下,GLP-2的作用得以保留。胰高血糖素样肽的生物学作用表明它们可能在糖尿病(GLP-1)或肠道疾病(GLP-2)中具有治疗效果。